Mustang Bio Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 4

Employees

  • Stock Symbol
  • MBIO

Stock Symbol

  • Share Price
  • $0.35
  • (As of Friday Closing)

Mustang Bio General Information

Description

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 95 Sawyer Road
  • Suite 110
  • Waltham, MA 02453
  • United States
+1 (781)
Primary Industry
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 95 Sawyer Road
  • Suite 110
  • Waltham, MA 02453
  • United States
+1 (781)

Mustang Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mustang Bio Stock Performance

As of 20-Nov-2026, Mustang Bio’s stock price is $0.35. Its current market cap is $2.69M with 7.58M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.35 $0.37 $0.35 - $1.43 $2.69M 7.58M 33.3K -$0.51

Mustang Bio Financials Summary

As of 30-Sep-2026, Mustang Bio has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (11,642) (11,824) 13,572 61,378
Revenue 0 0 0 0
EBITDA (3,956) (2,391) (15,108) (48,914)
Net Income (3,529) (1,921) (15,752) (51,602)
Total Assets 14,683 17,593 9,308 17,742
Total Debt 0 0 878 2,498
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mustang Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mustang Bio‘s full profile, request access.

Request a free trial

Mustang Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into
Drug Discovery
Waltham, MA
4 As of 2025

Berkeley, CA
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mustang Bio Competitors (84)

One of Mustang Bio’s 84 competitors is Caribou Biosciences, a Formerly VC-backed company based in Berkeley, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Caribou Biosciences Formerly VC-backed Berkeley, CA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Vor Biopharma Formerly VC-backed Boston, MA
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
Poseida Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 84 competitors. Get the full list »

Mustang Bio Patents

Mustang Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021342126-A1 Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer Inactive 10-Sep-2020
AU-2021342126-A9 Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer Inactive 10-Sep-2020
CA-3194747-A1 Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer Pending 10-Sep-2020
EP-4210831-A2 Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer Inactive 10-Sep-2020
US-20220072043-A1 Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer Pending 10-Sep-2020 A61K40/31
To view Mustang Bio’s complete patent history, request access »

Mustang Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mustang Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Mustang Bio‘s full profile, request access.

Request a free trial

Mustang Bio ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

40.55 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Mustang Bio’s complete esg history, request access »

Mustang Bio FAQs

  • When was Mustang Bio founded?

    Mustang Bio was founded in 2015.

  • Where is Mustang Bio headquartered?

    Mustang Bio is headquartered in Waltham, MA.

  • What is the size of Mustang Bio?

    Mustang Bio has 4 total employees.

  • What industry is Mustang Bio in?

    Mustang Bio’s primary industry is Drug Discovery.

  • Is Mustang Bio a private or public company?

    Mustang Bio is a Public company.

  • What is Mustang Bio’s stock symbol?

    The ticker symbol for Mustang Bio is MBIO.

  • What is the current stock price of Mustang Bio?

    As of 20-Nov-2026 the stock price of Mustang Bio is $0.35.

  • What is the current market cap of Mustang Bio?

    The current market capitalization of Mustang Bio is $2.69M.

  • Who are Mustang Bio’s competitors?

    Caribou Biosciences, Genetix Biotherapeutics, Vor Biopharma, Allogene Therapeutics, and Poseida Therapeutics are some of the 84 competitors of Mustang Bio.

  • What is Mustang Bio’s annual earnings per share (EPS)?

    Mustang Bio’s EPS for 12 months was -$0.51.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process